Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
David Adams(Mount Sinai Health System), Ole B. Suhr(Umeå University), Ivailo Tournev(Université Paris-Sud), Giuseppe Vita(University of Messina), John L. Berk(Boston University), Hartmut Schmidt(Université Paris-Sud), Sunita Goyal(Université Paris-Sud), Philip N. Hawkins(The Royal Free Hospital), Jared Gollob(Université Paris-Sud), Andrew Strahs(Université Paris-Sud), Josep M. Campistol(Universitat de Barcelona), Yoshiki Sekijima(Shinshu University), Violaine Planté‐Bordeneuve(Université Paris-Est Créteil), Mitsuharu Ueda(Kumamoto University), Scott D. Solomon(Brigham and Women's Hospital), Jeeyoung Oh(Université Paris-Sud), Chih‐Chao Yang(Université Paris-Sud), Thomas H. Brannagan(Columbia University), Arnt V. Kristen(Heidelberg University), Pushkal Garg(Université Paris-Sud), Akshay Vaishnaw(Alnylam Pharmaceuticals (United States)), Alejandra González‐Duarte(NYU Langone Health), Michael Polydefkis(Université Paris-Sud), Shahram Attarian(Aix-Marseille Université), Jihong Chen(Université Paris-Sud), Teresa Coelho(Universidade do Porto), Juan Buades(Université Paris-Sud), Byoung J. Kim(Université Paris-Sud), Kon-Ping Lin(Université Paris-Sud), Pritesh J. Gandhi(Université Paris-Sud), Saraswathy V. Nochur(Université Paris-Sud), William O’Riordan(Université Paris-Sud), Michelle M. Mezei(Université Paris-Sud), Marianne T. Sweetser(Alnylam Pharmaceuticals (United States)), Yeşim Parman(Université Paris-Sud), P. James B. Dyck(Mayo Clinic)
Cited by 2,911
Related Papers
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2022|2.6k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
|New England Journal of Medicine|2015|2.3k